PORT WASHINGTON, N.Y., November 04, 2011 - Pall Corporation (NYSE: PLL), today introduced the Pall Acrodisc® MS Syringe Filter the first syringe filter certified for low extractables in high performance liquid chromatography/mass spectrometry (LCMS) applications. Designed specifically for LCMS, the Acrodisc MS syringe filter improves the accuracy of testing, enhances LCMS performance, and extends the longevity of testing instrumentation.
Acrodisc MS Syringe Filter (Photo: Business Wire)
The low extractable levels of the new Acrodisc MS syringe filter minimize interference with the ionization process and reduce the need for retesting. This lowers costs while minimizing downtime due to unexpected contamination. To ensure high performance, product tubes are packaged individually so that filters not currently in use remain sealed and protected from external contamination.
Constructed with Pall’s new WWPTFE membrane in a high density polyethylene housing, the Acrodisc MS syringe filter can be used with both organic and aqueous solvents. It offers excellent chemical resistance, good particulate retention, and minimal protein adsorption. This protects instrument columns from particulate build-up and reduces the frequency and cost of replacement. It also enables more consistent LCMS testing performance.
“Pall’s Acrodisc MS syringe filter is the newest innovation in our comprehensive line of syringe filters and the first LCMS-certified syringe filter that is low in extractables,” said Larry O’Connell, senior vice president, Pall Global Lab Products. “It will improve the accuracy, cost, and reliability of high performance LCMS testing and the applications for this advancement are extensive.”
To learn more about the Acrodisc MS syringe filter and other Pall Life Sciences laboratory products, visit www.pall.com/lab.
About Pall Life Sciences
Pall Life Sciences provides cutting-edge products and services to meet the demanding needs of customers discovering, developing and producing biotech drugs, vaccines and classic pharmaceuticals. Pall technologies are also used to collect and process blood components and help protect patients from hospital-acquired infections. The company’s membranes and membrane devices optimize detection and sample preparation in the drug research, clinical diagnostics, genomics, and proteomics markets. Pall is a leading provider of separation systems and single-use filtration and purification technologies to pharmaceutical and biotechnology companies to support faster development of new drugs and vaccines that are safer and require less energy and water to produce.
About Pall Corporation
Pall Corporation (NSYE: PLL) is a filtration, separation and purification leader providing solutions to meet the critical fluid management needs of customers across the broad spectrum of life sciences and industry. Pall works with customers to advance health, safety and environmentally responsible technologies. The Company's engineered products enable process and product innovation and minimize emissions and waste. Pall Corporation, with total revenues of $2.7 billion for fiscal year 2011, is an S&P 500 company with almost 11,000 employees serving customers worldwide. Pall has been named a “top green company” by Newsweek magazine. To see how Pall is helping enable a greener, safer, more sustainable future, follow us on Twitter @PallCorporation or visit www.pall.com/green.